keyword
MENU ▼
Read by QxMD icon Read
search

Crohn's:8

keyword
https://www.readbyqxmd.com/read/28436109/efficiency-of-ustekinumab-in-crohn-s-disease-with-severe-psoriasiform-rash-induced-by-biotherapies-in-an-adolescent
#1
Valérie Bertrand, Abdelaziz El Haite, Delphine Carré
Ustekinumab is approved for the treatment of psoriasis in adolescents and for the treatment of moderate to severe Crohn's disease (CD) in adults, but data are lacking in pediatric CD. We report a case of severe psoriasis induced by biotherapies in an adolescent with CD that improved after switching to ustekinumab (90 mg at weeks 0, 2, and 4 and then every 8 weeks). The patient had not experienced CD relapse after 1 year of follow-up. Ustekinumab can be an alternative therapy for psoriasis induced by biotherapies when conventional treatment fails and can maintain remission of CD...
April 23, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28434027/can-ultrasound-be-used-as-the-primary-imaging-in-children-with-suspected-crohn-disease
#2
Timothy L Tsai, Megan B Marine, Matthew R Wanner, Matthew L Cooper, Steven J Steiner, Fangqian Ouyang, S Gregory Jennings, Boaz Karmazyn
BACKGROUND: There is growing literature on the use of ultrasound (US) for evaluation of Crohn disease in adults, but few studies have been conducted on children. Several studies demonstrated high accuracy of US in the diagnosis of Crohn disease. Using US as the primary screening imaging modality for Crohn disease can reduce health care costs, the need for sedation and ionizing radiation exposure. OBJECTIVE: The aim of our study is to determine if US can be used for screening evaluation of pediatric Crohn disease...
April 22, 2017: Pediatric Radiology
https://www.readbyqxmd.com/read/28431493/pan-intestinal-capsule-endoscopy-in-patients-with-postoperative-crohn-s-disease-a-pilot-study
#3
Johannes Hausmann, Renate Schmelz, Jens Walldorf, Natalie Filmann, Stefan Zeuzem, Jörg G Albert
BACKGROUND: Patients are at increased risk of disease recurrence after surgical treatment of Crohn's disease. Endoscopic detection of postoperative, ileo-colonic inflammation is well established, but the potential of pan-intestinal endoscopy is yet unknown. METHODS: This prospective multicenter pilot study assessed the value of pan-intestinal capsule endoscopy using a colon capsule endoscope for the detection of inflammatory recurrence of Crohn´s disease. Patients who had been operatively treated for Crohn´s disease were included...
April 21, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28430891/development-and-validation-of-diagnostic-criteria-for-ibd-subtypes-with-an-emphasis-on-ibd-unclassified-in-children-a-multicenter-study-from-the-pediatric-ibd-porto-group-of-espghan
#4
Liron Birimberg-Schwartz, David M Zucker, Amichay Akriv, Salvatore Cucchiara, Fiona L Cameron, David C Wilson, Iza Lazowska, Lambri Yianni, Siba Prosad Paul, Claudio Romano, Sanja Kolacek, Stephan Buderus, Anders Pærregaard, Richard K Russell, Johanna C Escher, Dan Turner
Background: The revised Porto criteria identify subtypes of pediatric inflammatory bowel diseases: ulcerative colitis (UC), atypical UC, Inflammatory Bowel Disease Unclassified (IBDU), and Crohn's disease (CD). In continuation of the Porto criteria, we aimed to derive and validate criteria for standardizing the classification of the IBD subtypes. Methods: This was a multicenter retrospective longitudinal study from 23 centers affiliated with the Porto-group of ESPGHAN...
April 18, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28426474/pouch-related-symptoms-and-quality-of-life-in-patients-with-ileal-pouch-anal-anastomosis
#5
Edward L Barnes, Hans H Herfarth, Robert S Sandler, Wenli Chen, Elizabeth Jaeger, Van M Nguyen, Amber R Robb, Michael D Kappelman, Christopher F Martin, Millie D Long
BACKGROUND: Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) has become the standard surgical treatment for the majority of patients with inflammatory bowel disease (IBD) who require colectomy. We evaluated the prevalence of pouch-related symptoms among the Crohn's and Colitis Foundation of America Partners cohort and the effect of pouch-related symptoms on Patient-Reported Outcome Measurement Information System measures. METHODS: We performed analyses nested in the Crohn's and Colitis Foundation of America Partners cohort...
April 19, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28426472/imaging-in-patients-with-crohn-s-disease-trends-in-abdominal-ct-mri-utilization-and-radiation-exposure-considerations-over-a-10-year-period
#6
Hamed Kordbacheh, Vinit Baliyan, Jessica Serrao, Michael S Gee, Vijay Yajnik, Dushyant V Sahani, Avinash R Kambadakone
PURPOSE: To study the trends in utilization of computed tomography (CT) and magnetic resonance imaging (MRI) in patients with Crohn's disease and to evaluate changes in CT radiation exposure over a 10-year period. METHODS: In this institutional review board-approved single-institution retrospective study, we included patients who underwent CT and MRIs for evaluation of Crohn's disease between 2006 and 2015. A total of 3196 CTs and 1924 MR scans were performed in 2156 patients (mean age: 34...
April 19, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28426458/anti-tnf%C3%AE-treatment-after-surgical-resection-for-crohn-s-disease-is-effective-despite-previous-pharmacodynamic-failure
#7
Amit Assa, Jiri Bronsky, Kaija-Leena Kolho, Kristyna Zarubova, Tim de Meij, Oren Ledder, Margaret Sladek, Stephanie van Biervliet, Caterina Strisciuglio, Raanan Shamir
BACKGROUND: The outcome of patients with Crohn's disease who failed anti-tumor necrosis factor alpha (anti-TNFα) therapy despite adequate serum drug levels (pharmacodynamic failure) is unclear. We aimed to assess such pediatric patients who underwent intestinal resection and were re-treated with the same anti-TNFα agent postoperatively. METHODS: Pediatric patients with Crohn's disease who underwent intestinal resection and were treated with anti-TNFα agents postoperatively were assessed retrospectively...
May 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28426457/race-differences-in-initial-presentation-early-treatment-and-1-year-outcomes-of-pediatric-crohn-s-disease-results-from-the-improvecarenow-network
#8
Jennifer L Dotson, Michele Cho, Josh Bricker, Michael D Kappelman, Deena J Chisolm, Gitit Tomer, Wallace V Crandall
BACKGROUND: Racially disparate care has been shown to contribute to suboptimal health care outcomes for minorities. Using the ImproveCareNow network, we investigated differences in management and outcomes of pediatric patients with Crohn's disease at diagnosis and 1-year postdiagnosis. METHODS: ImproveCareNow is a learning health network for pediatric inflammatory bowel disease. It contains prospective, longitudinal data from outpatient encounters. This retrospective study included all patients with Crohn's disease ≤21 years, September 2006 to October 2014, with the first recorded encounter ≤90 days from date of diagnosis and an encounter 1 year ±60 days...
May 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28426456/expression-and-localization-of-mir-21-and-mir-126-in-mucosal-tissue-from-patients-with-inflammatory-bowel-disease
#9
Gorm Thorlacius-Ussing, Boye Schnack Nielsen, Vibeke Andersen, Kim Holmstrøm, Anders E Pedersen
BACKGROUND: microRNAs (miRNAs) are small noncoding RNAs that guide degradation of mRNA and regulate protein expression. miRNA based diagnostic biomarkers for ulcerative colitis (UC) and Crohn's disease (CD) are emerging but information about the cellular localization of many miRNAs is limited and more detailed histologic evaluation of miRNA expression patterns is needed to understand their immunobiological function. METHODS: Formalin-fixed paraffin-embedded colon biopsies from 10 patients with UC and 8 patients with CD together with 9 controls were examined by RT-qPCR and quantitative in situ hybridization (ISH)...
May 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28426455/digoxin-attenuates-murine-experimental-colitis-by-downregulating-th17-related-cytokines
#10
Shinya Tani, Ryosuke Takano, Satoshi Tamura, Shinji Oishi, Moriya Iwaizumi, Yasushi Hamaya, Kosuke Takagaki, Toshi Nagata, Shintaro Seto, Toshinobu Horii, Isao Kosugi, Toshihide Iwashita, Satoshi Osawa, Takahisa Furuta, Hiroaki Miyajima, Ken Sugimoto
BACKGROUND: Digoxin, a cardiac glycoside used for the treatment of heart failure, was reported to inhibit the retinoid-related orphan receptor gamma t (RORγt) and attenuate the severity of experimental autoimmune encephalomyelitis and arthritis in mice. However, the effects of digoxin in a mice model of inflammatory bowel disease have not been elucidated. METHODS: Colitis was induced in severe combined immunodeficiency mice by adoptive transfer of CD45RB CD4 T cells...
May 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28426453/indications-for-mode-of-delivery-in-pregnant-women-with-inflammatory-bowel-disease
#11
Kristin E Burke, Miriam J Haviland, Michele R Hacker, Scott A Shainker, Adam S Cheifetz
BACKGROUND: Reasons for the increased incidence of cesarean delivery among women with inflammatory bowel disease remain unclear. We assessed cesarean delivery incidence and factors influencing mode of delivery in women with inflammatory bowel disease. METHODS: We performed a 10-year retrospective cohort study of nulliparous women who delivered a singleton infant at our institution. We compared the risk of each mode of delivery in women with Crohn's disease and ulcerative colitis with women without inflammatory bowel disease...
May 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28421251/defining-the-ultrasound-longitudinal-natural-history-of-newly-diagnosed-pediatric-small-bowel-crohn-disease-treated-with-infliximab-and-infliximab-azathioprine-combination-therapy
#12
Jonathan R Dillman, Soudabeh Fazeli Dehkordy, Ethan A Smith, Michael A DiPietro, Ramon Sanchez, Vera DeMatos-Maillard, Jeremy Adler, Bin Zhang, Andrew T Trout
BACKGROUND: Little is known about changes in the imaging appearances of the bowel and mesentery over time in either pediatric or adult patients with newly diagnosed small bowel Crohn disease treated with anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. OBJECTIVE: To define how bowel ultrasound findings change over time and correlate with laboratory inflammatory markers in children who have been newly diagnosed with pediatric small bowel Crohn disease and treated with infliximab...
April 18, 2017: Pediatric Radiology
https://www.readbyqxmd.com/read/28420280/enteric-coated-budesonide-for-the-induction-and-maintenance-of-remission-of-crohn-s-disease-in-children
#13
Stanley A Cohen, Marina Aloi, Ramalingam Arumugam, Robert Baker, Kevin Bax, Jaroslaw Kierkuś, Sibylle Koletzko, Paolo Lionetti, Tore Persson, Stefan Eklund
OBJECTIVE: These studies evaluated the safety and efficacy of enteric-coated budesonide for the induction and maintenance of remission of mild-to-moderate Crohn's disease (CD) in children. METHODS: The consecutive, multicenter, open-label, non-comparative studies enrolled patients aged 6-17 years. In the induction study, patients with active CD of the ileum and/or ascending colon received budesonide 9 mg or 6 mg once daily for 8 weeks; in the maintenance study, patients in remission received budesonide 6 mg once daily for 12 weeks...
April 19, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28416240/efficacy-of-tumour-necrosis-factor-antagonists-in-stricturing-crohn-s-disease-a-tertiary-center-real-life-experience
#14
Mariangela Allocca, Cristiana Bonifacio, Gionata Fiorino, Antonino Spinelli, Federica Furfaro, Luca Balzarini, Stefanos Bonovas, Silvio Danese
BACKGROUND: Stenosis is the most common complication of Crohn's disease (CD). Long-term outcome of patients receiving tumour necrosis factor (TNF) antagonists for such disease complication is poorly understood. METHODS: 51 CD patients (from July 2006 to November 2015) who had a diagnosis of small bowel or colonic stenosis, diagnosed by colonoscopy and/or MRI enterography, and were treated with TNF antagonists (adalimumab or infliximab) were enrolled. The primary outcome was to assess the rate of success of TNF antagonists on avoiding abdominal surgery for stricturing CD patients...
March 30, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28411872/induction-therapy-with-the-selective-interleukin-23-inhibitor-risankizumab-in-patients-with-moderate-to-severe-crohn-s-disease-a-randomised-double-blind-placebo-controlled-phase-2-study
#15
Brian G Feagan, William J Sandborn, Geert D'Haens, Julián Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Denis Franchimont, Olivier Dewit, Ursula Seidler, Kyung-Jo Kim, Markus F Neurath, Stefan Schreiber, Paul Scholl, Chandrasena Pamulapati, Bojan Lalovic, Sudha Visvanathan, Steven J Padula, Ivona Herichova, Adina Soaita, David B Hall, Wulf O Böcher
BACKGROUND: The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of risankizumab (BI 655066, Boehringer Ingelheim, Ingelheim, Germany), a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, in patients with moderately-to-severely active Crohn's disease. METHODS: In this randomised, double-blind, placebo-controlled phase 2 study, we enrolled patients at 36 referral sites in North America, Europe, and southeast Asia...
April 12, 2017: Lancet
https://www.readbyqxmd.com/read/28410345/development-of-a-novel-predictive-model-for-the-clinical-course-of-crohn-s-disease-results-from-the-connect-study
#16
Yehyun Park, Jae Hee Cheon, Yi Lang Park, Byong Duk Ye, You Sun Kim, Dong Soo Han, Joo Sung Kim, Sung Noh Hong, Young Ho Kim, Seong Ran Jeon, Won Ho Kim
BACKGROUND: A considerable number of patients with Crohn's disease (CD) develop irreversible intestinal damage, although the early administration of immunomodulatory or biological therapies might prevent this. The aims of our study were to develop and validate a novel predictive model that can be used to predict the risk of surgical intervention in Korean patients with CD. METHODS: The prognostic model was derived from the multicenter longitudinal CONNECT (CrOhn's disease cliNical NEtwork and CohorT) study cohort consisting of 1338 patients with CD, who were split into training and validation sets...
April 13, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28408997/endoscopic-balloon-dilatation-of-crohn-s-associated-intestinal-strictures-high-patient-satisfaction-and-long-term-efficacy
#17
Anna Rueda Guzmán, Jan Wehkamp, Andreas Kirschniak, Aline Naumann, Nisar P Malek, Martin Goetz
INTRODUCTION: Stricture formation is a common long-term complication of Crohn's disease. Endoscopic balloon dilatation offers a bowel-sparing treatment option, but long-term outcome and its association with patient-, stricture-, and procedure-related factors is only poorly understood. Patient satisfaction with endoscopic balloon dilatation is largely unknown. METHODS: We performed a retrospective review of all endoscopic balloon dilatation for Crohn's disease-related strictures between January 2005 and January 2013...
December 2016: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/28408996/risk-factors-for-complications-after-ileocolonic-resection-for-crohn-s-disease-with-a-major-focus-on-the-impact-of-preoperative-immunosuppressive-and-biologic-therapy-a-retrospective-international-multicentre-study
#18
Takayuki Yamamoto, Antonino Spinelli, Yasuo Suzuki, Rogerio Saad-Hossne, Fabio Vieira Teixeira, Idblan Carvalho de Albuquerque, Rodolff Nunes da Silva, Ivan Folchini de Barcelos, Ken Takeuchi, Akihiro Yamada, Takahiro Shimoyama, Lorete Maria da Silva Kotze, Matteo Sacchi, Silvio Danese, Paulo Gustavo Kotze
BACKGROUND: Author note: TY, AS, YS, FVT and PGK designed the study. All authors did data collection and gave scientific contribution to the study design and discussion. TY, AS and PGK drafted the article. All authors read and approved the final version of the manuscript.In the era of biologic agents, risk factors for complications following resection for Crohn's disease have not been fully identified. In particular, the association of preoperative use of immunosuppressive and biologic agents with the incidence of complications after resection remains to be elucidated...
December 2016: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/28405731/reduced-bone-mass-and-preserved-marrow-adipose-tissue-in-patients-with-inflammatory-bowel-diseases-in-long-term-remission
#19
C M Bastos, I M Araújo, M H Nogueira-Barbosa, C E G Salmon, F J A de Paula, L E A Troncon
Bone marrow adipose tissue has not been studied in patients with inactive inflammatory bowel disease. We found that these patients have preserved marrow adiposity even with low bone mass. Factors involved in bone loss in active disease may have long-lasting effects but do not seem to affect bone marrow adiposity. INTRODUCTION: Reduced bone mass is known to occur at varying prevalence in patients with inflammatory bowel diseases (IBD) because of inflammation, malnutrition, and steroid therapy...
April 12, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28402454/adalimumab-vs-azathioprine-in-the-prevention-of-postoperative-crohn-s-disease-recurrence-a-geteccu-randomized-trial
#20
Antonio López-Sanromán, Isabel Vera-Mendoza, Eugeni Domènech, Carlos Taxonera, Vicente Vega Ruiz, Ignacio Marín-Jiménez, Jordi Guardiola, Luisa Castro, María Esteve, Eva Iglesias, Daniel Ceballos, Pilar Martínez-Montiel, Javier P Gisbert, Miguel Mínguez, Ana Echarri, Xavier Calvet, Jesús Barrio, Joaquín Hinojosa, María Dolores Martín-Arranz, Lucía Márquez-Mosquera, Fernando Bermejo, Jordi Rimola, Vicente Pons, Pilar Nos
Background and Aims: Postoperative recurrence of Crohn's disease (POR-CD) is almost certain if no prophylaxis is administered. Evidence for optimal treatment is lacking. Our aim was to compare the efficacy of adalimumab (ADA) and azathioprine (AZA) in this setting. Methods: We performed a phase 3, 52-week, multicenter, randomized, superiority study (APPRECIA), in which patients with ileocolic resection were randomized either to ADA 160-80-40 mg SC or AZA 2.5 mg/kg/d, both associated to metronidazole...
April 11, 2017: Journal of Crohn's & Colitis
keyword
keyword
53050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"